RE: Sareum tweet again today.18 Sep 2018 14:08
Pfizer Inc. PFE announced positive top-line data from a phase IIa study evaluating its JAK3 inhibitor candidate, PF-06651600, and tyrosine kinase 2/JAK1 inhibitor, PF-06700841, as a treatment for moderate to severe alopecia areata (“AA”).
Both the candidates met the primary endpoint of improving hair regrowth on the scalp compared to baseline over 24 weeks of treatment. Data from the study was presented at the European Academy of Dermatology and Venereology Congress, which was held in France.